<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Entresto</title>
    <link rel="stylesheet" href="assets/css/bootstrap.min.css">
    <link rel="stylesheet" href="assets/css/style.css">


</head>

<body>


    <header id="header">
        <div class="header-top text-14">
            <div
                class="container text-center d-sm-flex align-items-center align-items-lg-start justify-content-between ">
                <a href="/" class="logo">
                    <img src="assets/images/logo.svg" alt="">
                </a>
                <div class="d-lg-flex mt-3">
                    <p class="text-color-primary mb-1 mb-lg-0">
                        For Canadian Healthcare Professionals
                    </p>
                    <div class="text-color-primary d-sm-flex align-items-start">
                        <a href="important-safety-information.html">
                            Important Safety Information
                        </a>
                        </a>
                        <a href="#">
                            Francais
                        </a>
                    </div>
                </div>
            </div>
        </div>
        <nav class="navbar navbar-expand-lg navbar-light bg-dark">
            <div class="container">
                <button class="navbar-toggler ms-auto" type="button" data-bs-toggle="collapse"
                    data-bs-target="#navbarSupportedContent" aria-controls="navbarSupportedContent"
                    aria-expanded="false" aria-label="Toggle navigation">
                    <span class="navbar-toggler-icon">
                        <svg viewBox="0 0 24 24" fill="#fff">
                            <path d="M3 18h18v-2H3v2zm0-5h18v-2H3v2zm0-7v2h18V6H3z"></path>
                        </svg>
                    </span>
                </button>
                <div class="collapse navbar-collapse" id="navbarSupportedContent">
                    <ul class="navbar-nav">
                        <li class="nav-item">
                            <a class="nav-link" href="entresto-efficacy.html">
                                Efficacy Data
                            </a>
                        </li>
                        <li class="nav-item">
                            <a class="nav-link active" href="entresto-safety-profile.html">
                                Safety Profile
                            </a>
                        </li>
                        <li class="nav-item">
                            <a class="nav-link" href="entresto-dosing.html">
                                Dosing
                            </a>
                        </li>
                        <li class="nav-item">
                            <a class="nav-link" href="entresto-moa.html">
                                Mechanism of Action
                            </a>
                        </li>
                        <li class="nav-item">
                            <a class="nav-link" href="hf-guidelines.html">
                                Guidelines
                            </a>
                        </li>
                        <li class="nav-item">
                            <a class="nav-link" href="entresto-resources.html">
                                Resources
                            </a>
                        </li>
                    </ul>
                </div>
            </div>
        </nav>
        <div class="header-bottom"></div>
    </header>

    <section class="page-content entresto-safety-profile">
        <div class="container">
            <h2 class="common-title-1">
                ENTRESTO<sup>®</sup>: A proven safety and tolerability profile in PARADIGM-HF
            </h2>
            <p class="text-18 pt-3">
                Because of the run-in design of the PARADIGM-HF trial, the adverse reaction rates in the randomized
                double-blind period of the trial may be lower than those expected to be seen in actual clinical
                practice.<sup>1†</sup>
            </p>
            <div class="esp-table">
                <h3 class="text-center mb-4 pb-2">
                    Summary of adverse events of interest occurring in ≥5% of patients <br class="d-none d-xl-block"> in
                    the randomized,
                    double-blind
                    phase of PARADIGM-HF<sup>1†</sup>
                </h3>
                <table>
                    <thead>
                        <tr>
                            <th>
                                <strong>
                                    ADVERSE EVENTS
                                </strong>
                            </th>
                            <th>
                                <strong>ENTRESTO<sup>®</sup> </strong>
                                <br>
                                N=4,203 (%)
                            </th>
                            <th>
                                <strong>Enalapril</strong>
                                <br>
                                N=4,229 (%)
                            </th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td>
                                Hypotension
                            </td>
                            <td>
                                17.6
                            </td>
                            <td>
                                12.0
                            </td>
                        </tr>
                        <tr>
                            <td>
                                Hyperkalemia
                            </td>
                            <td>
                                11.6
                            </td>
                            <td>
                                14.0
                            </td>
                        </tr>
                        <tr>
                            <td>
                                Renal impairment
                            </td>
                            <td>
                                10.1
                            </td>
                            <td>
                                11.5
                            </td>
                        </tr>
                        <tr>
                            <td>
                                Cough
                            </td>
                            <td>
                                8.8
                            </td>
                            <td>
                                12.6
                            </td>
                        </tr>
                        <tr>
                            <td>
                                Dizziness
                            </td>
                            <td>
                                6.3
                            </td>
                            <td>
                                4.9
                            </td>
                        </tr>
                        <tr>
                            <td>
                                Renal failure, including acute renal failure
                            </td>
                            <td>
                                4.9
                            </td>
                            <td>
                                5.6
                            </td>
                        </tr>
                    </tbody>
                </table>
                <div class="pt-4 text-14">
                    <span>
                        ENTRESTO<sup>®</sup> dosed up to 97.2 mg sacubitril/102.8 mg valsartan BID, enalapril dosed up
                        to 10 mg
                        BID. <br>
                        Adapted from the ENTRESTO<sup>®</sup> Product Monograph<sup>1</sup>
                    </span>
                </div>
            </div>
            <p class="text-18 my-5 py-4">
                ENTRESTO<sup>®</sup>-treated patients who experienced a hypotensive event in the double-blind treatment
                phase were
                more commonly observed to have other associated hypotensive adverse events, compared to
                enalapril-treated patients, such as post-baseline systolic blood pressure (SBP) &lt;90 mmHg (5.2% vs.
                3.1%, respectively), a drop ≥30 mmHg in SBP from baseline (5.4% vs. 3.2%), and simultaneous symptomatic
                hypotension and SBP &lt;90 mmHg (2.8% vs. 1.5%).
            </p>

            <div class="bg-yellow px-3 text-center text-22 py-4 mt-5">
                <strong>Discontinuation of therapy</strong>
                due to an adverse event in the double-blind period of the
                PARADIGM-HF <br class="d-none d-xl-block">
                trial <strong>occurred in 10.7% of ENTRESTO<sup>®</sup>-treated patients vs. 12.2% of enalapril-treated
                    patients.<sup>1†</sup></strong>
            </div>
            <div class="common-block reference-block mt-5 pt-lg-5">
                <table>
                    <tr>
                        <td style="vertical-align: top;">†</td>
                        <td>In the PARADIGM-HF trial, patients were required to complete sequential single-blind enalapril and
                            ENTRESTO<sup>®</sup> run-in periods of a median duration of 15 and 29 days,
                            respectively, prior to entering the randomized double-blind period, comparing ENTRESTO<sup>®</sup>
                            and
                            enalapril. During the enalapril run-in period,1,102 patients (10.5%) were
                            permanently discontinued from the study, 5.6% because of an adverse event, most commonly renal
                            dysfunction (1.7%), hyperkalemia (1.7%) and hypotension (1.4%).
                            During the ENTRESTO<sup>®</sup> run-in period, which followed the enalapril run-in phase, an
                            additional 10.4%
                            of patients permanently discontinued treatment, 5.9% because of an
                            adverse event, most commonly renal dysfunction (1.8%), hypotension (1.7%) and hyperkalemia (1.3%).</td>
                    </tr>
                </table>
            </div>
        </div>
    </section>

    <footer>
        <div class="container">
            <div class="links text-center text-lg-start mb-4 mb-lg-0">
                <a href="privacy-policy.html">
                    Privacy Policy
                </a>
                |
                <a href="terms-of-use.html">
                    Terms of Use
                </a>
                | <a href="#">
                    Cookie Settings
                </a>
            </div>
            <div class="d-flex align-items-lg-end flex-column flex-lg-row">
                <a href="#">
                    <img src="assets/images/footer-logo.svg" alt="">
                </a>
                <p class="mt-3 mt-lg-0">
                    Entresto is a registered trademark. <br>
                    © Novartis Pharmaceuticals Canada Inc. 2022
                </p>
                <div class="footer-right mt-2 mt-lg-0">
                    <p class="mb-3 mb-lg-0">
                        187298E - July 2022
                    </p>
                    <img src="assets/images/footer-img-2.svg" alt="">
                    <img src="assets/images/footer-img-3.svg" alt="">
                </div>
            </div>
        </div>
    </footer>

    <script src="assets/js/jquery.js"></script>
    <script src="assets/js/bootstrap.bundle.min.js"></script>
    <script src="assets/js/index.js"></script>
    <script>

    </script>
</body>

</html>